Moleculin Biotech, Inc. announced that it has received approval from the United Kingdom’s MHRA to proceed with a first-in-human Phase Ia study to evaluate the safety and pharmacokinetics of WP1122 in healthy volunteers for the treatment of COVID-19.
[Moleculin Biotech, Inc.]